eARDS: A multi-center validation of an interpretable machine learning algorithm of early onset Acute Respiratory Distress Syndrome (ARDS) among critically ill adults with COVID-19.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2021
accepted:
21
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
5
10
2021
Statut:
epublish
Résumé
We present an interpretable machine learning algorithm called 'eARDS' for predicting ARDS in an ICU population comprising COVID-19 patients, up to 12-hours before satisfying the Berlin clinical criteria. The analysis was conducted on data collected from the Intensive care units (ICU) at Emory Healthcare, Atlanta, GA and University of Tennessee Health Science Center, Memphis, TN and the Cerner® Health Facts Deidentified Database, a multi-site COVID-19 EMR database. The participants in the analysis consisted of adults over 18 years of age. Clinical data from 35,804 patients who developed ARDS and controls were used to generate predictive models that identify risk for ARDS onset up to 12-hours before satisfying the Berlin criteria. We identified salient features from the electronic medical record that predicted respiratory failure among this population. The machine learning algorithm which provided the best performance exhibited AUROC of 0.89 (95% CI = 0.88-0.90), sensitivity of 0.77 (95% CI = 0.75-0.78), specificity 0.85 (95% CI = 085-0.86). Validation performance across two separate health systems (comprising 899 COVID-19 patients) exhibited AUROC of 0.82 (0.81-0.83) and 0.89 (0.87, 0.90). Important features for prediction of ARDS included minimum oxygen saturation (SpO2), standard deviation of the systolic blood pressure (SBP), O2 flow, and maximum respiratory rate over an observational window of 16-hours. Analyzing the performance of the model across various cohorts indicates that the model performed best among a younger age group (18-40) (AUROC = 0.93 [0.92-0.94]), compared to an older age group (80+) (AUROC = 0.81 [0.81-0.82]). The model performance was comparable on both male and female groups, but performed significantly better on the severe ARDS group compared to the mild and moderate groups. The eARDS system demonstrated robust performance for predicting COVID19 patients who developed ARDS at least 12-hours before the Berlin clinical criteria, across two independent health systems.
Identifiants
pubmed: 34559819
doi: 10.1371/journal.pone.0257056
pii: PONE-D-21-13104
pmc: PMC8462682
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257056Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR002382
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM095442
Pays : United States
Organisme : NIH HHS
ID : 2T32 GM095442
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NIGMS NIH HHS
ID : K23 GM137182
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2006 Jun 15;354(24):2564-75
pubmed: 16714767
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Eur Respir J. 2020 May 21;55(5):
pubmed: 32341111
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:1667-70
pubmed: 19964545
Crit Care Explor. 2020 Oct 23;2(10):e0262
pubmed: 33134950
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
JAMA. 2012 Oct 24;308(16):1651-9
pubmed: 23093163
Shock. 2021 Jul 1;56(1):58-64
pubmed: 32991797
J Intensive Care. 2020 Oct 12;8:78
pubmed: 33062283
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Sci Rep. 2019 Aug 2;9(1):11270
pubmed: 31375728
Eur Respir J. 2011 Mar;37(3):604-9
pubmed: 20562130
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Am J Respir Crit Care Med. 2005 Feb 1;171(3):242-8
pubmed: 15557131
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
PLoS One. 2019 Mar 28;14(3):e0214465
pubmed: 30921400
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Pediatr Crit Care Med. 2018 Oct;19(10):e495-e503
pubmed: 30052552
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Front Immunol. 2021 Feb 22;12:592303
pubmed: 33692779
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Respir Med. 2020 Aug;8(8):816-821
pubmed: 32645311
J Crit Care. 2020 Dec;60:169-176
pubmed: 32854088
J Transl Med. 2019 Oct 1;17(1):326
pubmed: 31570096
AMIA Annu Symp Proc. 2018 Apr 16;2017:883-891
pubmed: 29854155
Intensive Care Med. 2012 Oct;38(10):1573-82
pubmed: 22926653
J Crit Care. 2020 Dec;60:96-102
pubmed: 32777759
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Intensive Care Med. 2020 Jun;46(6):1180-1183
pubmed: 32328723
Am J Respir Crit Care Med. 2005 Nov 15;172(10):1241-5
pubmed: 16081547
Chest. 2018 Feb;153(2):361-367
pubmed: 29248620
Crit Care Med. 2020 Nov;48(11):e1045-e1053
pubmed: 32804790
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
JAMA. 2020 Jun 2;323(21):2195-2198
pubmed: 32329797
AMIA Annu Symp Proc. 2018 Dec 05;2018:157-165
pubmed: 30815053
Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa421
pubmed: 33072814
Am J Respir Crit Care Med. 2015 Jan 15;191(2):177-85
pubmed: 25478681
Crit Care Med. 2016 Dec;44(12):2182-2191
pubmed: 27513358